CRME Share Price

Open 2.59 Change Price %
High 2.69 1 Day -0.49 -18.85
Low 2.11 1 Week -1.80 -46.04
Close 2.11 1 Month -2.59 -55.11
Volume 776546 1 Year -0.97 -31.49
52 Week High 4.84
52 Week Low 2.11
CRME Important Levels
Resistance 2 2.65
Resistance 1 2.43
Pivot 2.30
Support 1 1.79
Support 2 1.57
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DCTH 0.13 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.03 50.00%
LOCM 0.09 50.00%
VRTA 4.50 38.46%
ATEA 2.50 32.98%
ATEA 2.50 32.98%
KIRK 10.98 31.03%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
TWER 0.10 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Cardiome Pharma Corporation (NASDAQ: CRME)

CRME Technical Analysis 5
As on 22nd Aug 2017 CRME Share Price closed @ 2.11 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.31 & Strong Sell for SHORT-TERM with Stoploss of 4.14 we also expect STOCK to react on Following IMPORTANT LEVELS.
CRME Target for August
1st Target up-side 4.59
2nd Target up-side 4.85
3rd Target up-side 5.11
1st Target down-side 3.83
2nd Target down-side 3.57
3rd Target down-side 3.31
CRME Other Details
Segment EQ
Market Capital 17544050.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.cardiome.com
CRME Address
CRME
6190 Agronomy Road
Suite 405
Vancouver, BC V6T 1Z3
Canada
Phone: 604-677-6905
Fax: 604-677-6915
CRME Latest News
Interactive Technical Analysis Chart Cardiome Pharma Corporation ( CRME NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cardiome Pharma Corporation
CRME Business Profile
Cardiome Pharma Corp. (Cardiome) is a research-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of new therapies. It has one product, BRINAVESS, approved for marketing in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The Company�s clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. Cardiome also has several pre-clinical projects directed at various therapeutic indications. The Company operates primarily in one business segment with all of its assets located in Canada and operations located in Canada, the United States, Switzerland and the United Kingdom. In March 2012, the Company announced that Merck & Co., Inc. (Merck) discontinued further development of vernakalant (oral). In November 2013, Cardiome Pharma Corp. completed the acquisition of Correvio LLC.